Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2026-05-22 Director's Dealing
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a statutory ‘임원·주요주주 특정증권등 소유상황보고서’ filed with the Securities and Futures Commission and Korea Exchange, detailing a director’s personal share ownership and changes (insider acquisition of 12,500 shares). This matches the “Director’s Dealing” category for insider transactions by executives. Thus, the correct classification is DIRS.
2026-05-22 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory “신고” (disclosure) to the Financial Services Commission/Korea Exchange correcting a previously filed stock‐option grant notice. It does not present financial statements (ruling out IR/10-K/AR), nor is it a general meeting result (DVA), director trades (DIRS), dividend (DIV), or M&A (TAR). It is a specific compliance filing for a stock‐option grant correction, which does not fit into the other more substantive report categories. Hence it is classified as a general Regulatory Filing (RNS).
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” and covers the period 2026-01-01 to 2026-03-31 for Chabiotech Co., Ltd. It includes detailed substantive sections (company overview, business activities, history, capital changes, subsidiaries, share capital, etc.). This is a full interim/quarterly financial report rather than just an announcement or summary. It therefore falls under the Interim / Quarterly Report category. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' which translates to 'Report on Large Shareholding Status'. It contains detailed information about shareholdings, changes in share ownership, related parties, and contractual details such as stock pledge loans. The document references specific dates in 2026 and includes detailed tables of share counts and ownership percentages. It is a regulatory filing related to disclosure of major shareholdings and changes thereof, consistent with notifications required under capital market laws. There is no indication that this is an annual report, earnings release, or management report. It is not a proxy statement or voting result announcement. The content matches the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels crossing thresholds.
2026-05-06 Korean
기업설명회(IR)개최
Investor Presentation Classification · 85% confidence The document is an announcement for a corporate investor relations meeting (“기업설명회(IR) 개최”) including date, time, participants, and where IR materials will be posted online. This is not a full financial report or a voting or regulatory notice, but rather an investor presentation event announcement. It best fits the “Investor Presentation (IP)” category.
2026-04-27 Korean
타법인주식및출자증권처분결정
Regulatory Filings Classification · 85% confidence The document is a corporate disclosure in Korean titled “타법인주식및출자증권처분결정” which outlines the decision by Cha Biotech to dispose of equity interests in its subsidiary. It contains details of shares sold, prices, board resolution dates, and related terms. It is not an earnings release, annual or interim report, nor a meeting presentation or voting result. It is a specific transaction announcement that does not match “Transaction in Own Shares” (which covers buybacks or issuer share transactions) nor pure capital raising or M&A takeover proposals. Therefore it falls into the general regulatory announcement fallback category.
2026-04-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.